Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sanofi Myeloma Drug Shines But Darzalex Dominates Still

Executive Summary

While data on Sanofi's anti-CD38 antibody isatuximab impressed at ASCO, analysts believe that the position of Johnson & Johnson's Darzalex in the multiple myeloma space is unlikely to be threatened.

You may also be interested in...



Sanofi Bets Big On IO With Synthorx Buy

The French drugmaker is paying $2.5bn to get hold of THOR-707 which it claims has the potential to become the best-in-class IL-2 therapeutic for solid tumors, thanks to improved pharmacology and less frequent dosing.

ASH Preview: J&J And Legend’s CAR-T Takes Center Stage

While bluebird bio, Celgene and GSK prepare to file, it’s time to shine for another myeloma contender.

Sanofi's New CEO Paul Hudson Poised To Write The Next Chapter

Less than one month into the job, Sanofi CEO Paul Hudson talked about his early perspective on how he can build on Sanofi's strengths and deliver needed changes.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC125324

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel